Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 7, Pages 1568
Publisher
MDPI AG
Online
2021-03-30
DOI
10.3390/cancers13071568
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A modular and controllable T cell therapy platform for acute myeloid leukemia
- (2021) Mohamed-Reda Benmebarek et al. LEUKEMIA
- Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
- (2021) Simon Wisnovsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets
- (2020) Zachary Davis et al. BLOOD
- Deletion of CISH in Human Pluripotent Stem Cell-Derived Natural Killer Cells Enhances Anti-Tumor Activity Via Metabolic Reprogramming
- (2020) Huang Zhu et al. BLOOD
- Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
- (2020) Naval G. Daver et al. BLOOD
- The therapeutic landscape for cells engineered with chimeric antigen receptors
- (2020) Matthew MacKay et al. NATURE BIOTECHNOLOGY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- CRISPR-engineered T cells in patients with refractory cancer
- (2020) Edward A. Stadtmauer et al. SCIENCE
- NK Cell-Based Immune Checkpoint Inhibition
- (2020) Muhammad Khan et al. Frontiers in Immunology
- Targeting Natural Killer Cells for Tumor Immunotherapy
- (2020) Cai Zhang et al. Frontiers in Immunology
- Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity
- (2020) Jing Ni et al. IMMUNITY
- Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance
- (2020) Valerie Barbier et al. Nature Communications
- You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
- (2020) Aline Pfefferle et al. Cancers
- Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2020) M. Heuser et al. ANNALS OF ONCOLOGY
- CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity
- (2020) Meisam Naeimi Kararoudi et al. BLOOD
- CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
- (2020) Margery Gang et al. BLOOD
- Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
- (2020) Keerthana Shankar et al. Stem Cell Research & Therapy
- Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways
- (2020) Rui Teng et al. Journal of Immunology Research
- Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia
- (2020) Isabel Valhondo et al. Cancers
- Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
- (2020) Xiaomei Wang et al. Blood Advances
- Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells
- (2020) May Daher et al. BLOOD
- Use of an anti‐CD200‐blocking antibody improves immune responses to AML in vitro and in vivo
- (2020) Namrata Rastogi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells
- (2020) Upasana Sunil Arvindam et al. LEUKEMIA
- CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia
- (2020) Guozhu Xie et al. Nature Biomedical Engineering
- Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML
- (2020) Harald Herrmann et al. Blood Advances
- CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
- (2020) Mark Gurney et al. HAEMATOLOGICA
- A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia
- (2020) Pierre Peterlin et al. Cancer Medicine
- Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity
- (2020) Marlon Arnone et al. Cancers
- Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes
- (2020) Silvia Pesce et al. Cancers
- Next-generation cell therapies: the emerging role of CAR-NK cells
- (2020) Rafet Basar et al. Blood Advances
- Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells
- (2019) Locke D. Uppendahl et al. GYNECOLOGIC ONCOLOGY
- The First Step in Adoptive Cell Immunotherapeutics: Assuring Cell Delivery via Glycoengineering
- (2019) Robert Sackstein Frontiers in Immunology
- A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia
- (2019) Rosa Nguyen et al. Journal for ImmunoTherapy of Cancer
- Mechanisms of resistance to CAR T cell therapy
- (2019) Nirali N. Shah et al. Nature Reviews Clinical Oncology
- Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients
- (2019) Lin Xiao et al. MOLECULAR THERAPY
- Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
- (2019) Matthew R. Collinson-Pautz et al. LEUKEMIA
- Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer–Based “Off-the-Shelf” Acute Myeloid Leukemia Immunotherapies
- (2019) Stephan Kloess et al. HUMAN GENE THERAPY
- Chimeric antigen receptor T cell persistence and memory cell formation
- (2019) Alexander D McLellan et al. IMMUNOLOGY AND CELL BIOLOGY
- Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
- (2019) Takahiro Kamiya et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia
- (2019) Melanie Märklin et al. Journal for ImmunoTherapy of Cancer
- Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
- (2019) Katherine D. Cummins et al. HAEMATOLOGICA
- IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
- (2019) Li-Chuan Chan et al. JOURNAL OF CLINICAL INVESTIGATION
- IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma
- (2019) Jian Wu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- NK cells switch from granzyme B to death receptor–mediated cytotoxicity during serial killing
- (2019) Isabel Prager et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
- (2019) Anna M. Paczulla et al. NATURE
- T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
- (2019) Aude G. Chapuis et al. NATURE MEDICINE
- Enhanced Bone Marrow Homing of Natural Killer Cells Following mRNA Transfection With Gain-of-Function Variant CXCR4R334X
- (2019) Emily Levy et al. Frontiers in Immunology
- MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
- (2019) Livingstone Fultang et al. EBioMedicine
- The Role of TRAIL/DRs in the Modulation of Immune Cells and Responses
- (2019) Duygu Sag et al. Cancers
- Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
- (2019) Caitlin L. Costello et al. BLOOD
- NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death
- (2019) Frank Cichocki et al. BLOOD
- Targeting CD38high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells
- (2019) Emma Nolan et al. BLOOD
- Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
- (2019) David A Sallman et al. BLOOD
- CD33 expression on natural killer cells is a potential confounder for residual disease detection in acute myeloid leukemia by flow cytometry
- (2019) Ashley M. Eckel et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
- (2019) Mattias Carlsten et al. Frontiers in Immunology
- The Graft-Versus-Leukemia Effect in AML
- (2019) Connor Sweeney et al. Frontiers in Oncology
- The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience
- (2019) Justin Loke et al. BRITISH JOURNAL OF HAEMATOLOGY
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
- (2018) Rizwan Romee et al. BLOOD
- Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses
- (2018) Jang Hwan Cho et al. CELL
- Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia
- (2018) Miriam Y. Kim et al. CELL
- Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity
- (2018) Ye Li et al. Cell Stem Cell
- Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
- (2018) Andreas T. Björklund et al. CLINICAL CANCER RESEARCH
- An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia
- (2018) Bing Zheng et al. CLINICAL CANCER RESEARCH
- The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation
- (2018) Alessandra Roberto et al. HAEMATOLOGICA
- NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.
- (2018) David A. Sallman et al. HAEMATOLOGICA
- A Developed NK-92MI Cell Line with Siglec-7neg Phenotype Exhibits High and Sustainable Cytotoxicity against Leukemia Cells
- (2018) Chin-Han Huang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
- (2018) Jinghua Wang et al. Journal of Hematology & Oncology
- PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
- (2018) Wenting Zheng et al. LEUKEMIA
- Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
- (2018) S. Haubner et al. LEUKEMIA
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
- (2018) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural Killer Cell Education and the Response to Infection and Cancer Therapy: Stay Tuned
- (2018) Jeanette E. Boudreau et al. TRENDS IN IMMUNOLOGY
- The early expansion of anergic NKG2Apos/CD56dim/CD16neg natural killer cells represents a therapeutic target in haploidentical haematopoietic stem cell transplantation
- (2018) Alessandra Roberto et al. HAEMATOLOGICA
- NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient.
- (2018) David A. Sallman et al. HAEMATOLOGICA
- Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors
- (2018) Vincent Yi Sheng Oei et al. Cancer Immunology Research
- Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia
- (2018) Jeffrey Baron et al. Expert Review of Clinical Pharmacology
- NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment
- (2018) Niken M. Mahaweni et al. Frontiers in Immunology
- Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
- (2018) Aude Le Roy et al. Frontiers in Immunology
- Human AML activates the AHR pathway to impair NK cell development and function
- (2018) Steven D. Scoville et al. BLOOD
- CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia
- (2018) Jyoti Naik et al. HAEMATOLOGICA
- Natural Killer Cells: Development, Maturation, and Clinical Utilization
- (2018) Alex M. Abel et al. Frontiers in Immunology
- Post-transplant immunotherapy with WT1-specific CTLs for high-risk acute myelogenous leukemia: a prospective clinical phase I/II trial
- (2018) Hee-Je Kim et al. BONE MARROW TRANSPLANTATION
- Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system
- (2018) Michael Hudecek et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Natural Killer Cell Homing and Persistence in the Bone Marrow After Adoptive Immunotherapy Correlates With Better Leukemia Control
- (2018) Bartosz Grzywacz et al. JOURNAL OF IMMUNOTHERAPY
- CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia
- (2018) Diogo Gomes-Silva et al. MOLECULAR THERAPY
- Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
- (2018) Daniel A. Pollyea et al. NATURE MEDICINE
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells
- (2017) Stephan Klöß et al. HUMAN GENE THERAPY
- Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia
- (2017) E Bernson et al. LEUKEMIA
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Tracing the origins of relapse in acute myeloid leukaemia to stem cells
- (2017) Liran I. Shlush et al. NATURE
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset
- (2017) Stephan Kloess et al. Frontiers in Immunology
- Kinetics of Cytotoxic Lymphocytes Reconstitution after Induction Chemotherapy in Elderly AML Patients Reveals Progressive Recovery of Normal Phenotypic and Functional Features in NK Cells
- (2017) Jérôme Rey et al. Frontiers in Immunology
- How important is NK alloreactivity and KIR in allogeneic transplantation?
- (2016) Brian C. Shaffer et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
- (2016) G. Olombel et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells
- (2016) Dhifaf Sarhan et al. CANCER RESEARCH
- Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients
- (2016) A. Curti et al. CLINICAL CANCER RESEARCH
- Potent Anti-leukemia Activities of Chimeric Antigen Receptor–Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
- (2016) Yongxian Hu et al. CLINICAL CANCER RESEARCH
- IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
- (2016) D. A. Vallera et al. CLINICAL CANCER RESEARCH
- MicroRNA-29b mediates altered innate immune development in acute leukemia
- (2016) Bethany L. Mundy-Bosse et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
- (2016) Partow Kebriaei et al. JOURNAL OF CLINICAL INVESTIGATION
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
- (2016) Rizwan Romee et al. Science Translational Medicine
- Repression of GSK3 restores NK cell cytotoxicity in AML patients
- (2016) Reshmi Parameswaran et al. Nature Communications
- Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing
- (2016) Conor J. Kearney et al. OncoImmunology
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- Soluble NKG2D ligand promotes MDSC expansion and skews macrophage to the alternatively activated phenotype
- (2015) Gang Xiao et al. Journal of Hematology & Oncology
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
- (2015) Quan-shun Wang et al. MOLECULAR THERAPY
- Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer
- (2015) David L. Hermanson et al. STEM CELLS
- Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
- (2015) L. Ruggeri et al. HAEMATOLOGICA
- Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein
- (2014) V. Bachanova et al. BLOOD
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
- (2014) S. Gill et al. BLOOD
- Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
- (2014) A Baragaño Raneros et al. GENES AND IMMUNITY
- Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia
- (2014) K. Stringaris et al. HAEMATOLOGICA
- Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
- (2014) X. Wei Meng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Donor Killer Cell Ig-like Receptor B Haplotypes, Recipient HLA-C1, and HLA-C Mismatch Enhance the Clinical Benefit of Unrelated Transplantation for Acute Myelogenous Leukemia
- (2014) S. Cooley et al. JOURNAL OF IMMUNOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
- (2014) A Ehninger et al. Blood Cancer Journal
- Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9
- (2013) Kristina Fritsch et al. ANNALS OF HEMATOLOGY
- A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells
- (2013) Y.-H. Chang et al. CANCER RESEARCH
- Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC
- (2013) Mirna Balsamo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Membrane-bound TRAIL Supplements Natural Killer Cell Cytotoxicity Against Neuroblastoma Cells
- (2013) Michael A. Sheard et al. JOURNAL OF IMMUNOTHERAPY
- Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
- (2013) David S. Ritchie et al. MOLECULAR THERAPY
- The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells
- (2013) Shiguo Zhu et al. PHARMACEUTICAL RESEARCH
- Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis
- (2012) J. Aurelius et al. BLOOD
- Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells
- (2012) S. Gill et al. BLOOD
- Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
- (2012) J. Hilpert et al. JOURNAL OF IMMUNOLOGY
- Receptor Activator for NF- B Ligand in Acute Myeloid Leukemia: Expression, Function, and Modulation of NK Cell Immunosurveillance
- (2012) B. J. Schmiedel et al. JOURNAL OF IMMUNOLOGY
- HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1
- (2012) Jeffrey M. Venstrom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor- 1
- (2011) M. J. Szczepanski et al. HAEMATOLOGICA
- TRAIL/DR5 Plays a Critical Role in NK Cell-Mediated Negative Regulation of Dendritic Cell Cross-Priming of T Cells
- (2011) M. Iyori et al. JOURNAL OF IMMUNOLOGY
- CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia
- (2011) S J Coles et al. LEUKEMIA
- The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
- (2011) Marianne van Dijk et al. Cancers
- Targeting AML through DR4 with a novel variant of rhTRAIL
- (2010) Eva Szegezdi et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia
- (2010) Jeffrey E. Rubnitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors
- (2009) Y. T. Bryceson et al. BLOOD
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment
- (2009) A. Barber et al. JOURNAL OF IMMUNOLOGY
- Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate
- (2009) A Poggi et al. LEUKEMIA
- The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
- (2008) A. Curti et al. BLOOD
- HLA-E upregulation on IFN-γ-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT
- (2008) S Nguyen et al. BONE MARROW TRANSPLANTATION
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- Functions of natural killer cells
- (2008) Eric Vivier et al. NATURE IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now